Array BioPharma Inc

Type: Company
Name: Array BioPharma Inc
Nationality: United States
Web Address: http://www.arraybiopharma.com/
First reported Sep 29 2014 - Updated 20 hours ago - 3 reports

Array's Melanoma Drug Promising in Phase 2

Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain.Invented by Array BioPharma Inc. and licensed to Novartis ... [Published Drug Discovery and Development - 20 hours ago]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

Array Biopharma : Patent Issued for Hydroxylated Pyrimidyl Cyclopentanes as Akt Protein Kinase Inhibitors

By a News Reporter-Staff News Editor at Biotech Week -- From Alexandria, Virginia , NewsRx journalists report that a patent by the inventors Bencsik, Josef R. ( Boulder, CO ); Blake, James F. ( Boulder, CO ); Kallan, Nicholas C. ( Boulder, CO ); Mitchell, ... [Published 4 Traders - Sep 24 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma

LONDONThe US markets on Friday, September 19, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,279.74, up 0.08% and the NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P 500 finished the session 0.05% lower at 2,010.40. ... [Published Bio-Medicine - Sep 22 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Array BioPharma, Inc. (ARRY) Appoints Victor Sandor, M.D., As Chief Medical Officer

BOULDER, Colo., Sept. 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced ... [Published FierceBiotech - Sep 19 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Array appoints Victor Sandor chief medical officer

Array Biopharma has named Victor Sandor as its new chief medical officer, handing him responsibility for leading clinical, medical and regulatory strategy and operations across its Array portfolio.This includes the Colorado, US-based company's binimetinic, ... [Published PMLive - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Allergic Rhinitis Treatment Market Global Technology Forecast 2019

Allergic Rhinitis is a chronic inflammatory disease of the nasal cavity which causes respiratory problems and affects all age groups. Common symptoms of the disease include sneezing, sore throat, nasal itching and blocked or running nose. The disease ... [Published MyNewsDesk - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 2 reports

Loxo Oncology Announces Second Quarter 2014 Financial Results

STAMFORD, Conn., Sept. 12, 2014 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO) ("Loxo"), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, today reported financial results for the quarter ... [Published Virtual Strategy Magazine - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 5 reports

Array BioPharma hires Dr Victor Sandor as CMO for late-stage clinical programmes

Biopharmaceutical company Array BioPharma (NasdaqGM:ARRY) reported on Thursday that it has appointed Dr Victor Sandor, MD as its chief medical officer. In his new role, Dr Sandor will replace the company's chief medical officer Dr Michael Needle.Dr Sandor ... [Published Individual.com - Sep 12 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Array BioPharma's (ARRY) CEO Ron Squarer at Morgan Stanley 2014 Global Healthcare Conference (Transcript)

Matthew Palmer - Morgan StanleyWe'll go ahead and get started now. Good afternoon and welcome to the Morgan Stanley Global Healthcare Conference. My name is Matthew Palmer and I am a member of the Biotechnology Equity Research team here at Morgan Sta ... [Published Seeking Alpha - Sep 10 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

June 2015 Options Now Available For Array BioPharma (ARRY)

Investors in Array BioPharma Inc. (ARRY) saw new options begin trading today, for the June 2015 expiration.. ... [Published Crawford Financial Planning - Sep 10 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 3 reports

Array BioPharma To Present At The Morgan Stanley 2014 Global Healthcare Conference

BOULDER, Colo.About Array BioPharmaArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies ... [Published ADVFN UK - Sep 03 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Array BioPharma Q4 net loss up

Array BioPharma Inc., a biopharmaceutical company, has reported that net loss for the fourth quarter ended June 30, 2014 was $28.24 million, or $0.22 loss per share, compared to a net loss of $17.65 million, or $0.15 loss per share, for the same quarter ... [Published Individual.com - Sep 01 2014]

Quotes

...have no targeted treatment available and prognosis is poor," said Reinhard Dummer, of the University of Zurich Hospital in Zurich, Switzerland.   "These data reinforce our view that binimetinib is an important new potential treatment option for these patients and I look forward to seeing the results from the ongoing Phase 3 NEMO trial to validate these findings."
"An additional aspect of the invention is the use of a compound of Formula I, or an enantiomer, solvate, metabolite, or pharmaceutically acceptable salt or prodrug thereof, for therapy. In one embodiment, the therapy comprises the treatment of an AKT protein kinase-mediated condition."

More Content

All (65) | News (31) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (0) | Press Releases (7)
sort by: Date | Relevance
Array's Melanoma Drug Promising in Phase 2 [Published Drug Discovery and Development - 20 hours ago]
Phase 2 Trial Of Binimetinib In NRAS Melanoma S... [Published Wall Street Select - Sep 29 2014]
Phase 2 Trial Of Binimetinib In NRAS Melanoma S... [Published PR Newswire: Health - Sep 29 2014]
Array Biopharma : Patent Issued for Hydroxylate... [Published 4 Traders - Sep 24 2014]
Stock Updates on Biotech Industry - Array BioPh... [Published Bio-Medicine - Sep 22 2014]
Stock Updates on Biotech Industry - Array BioPh... [Published Financial Services - Sep 22 2014]
Array BioPharma, Inc. (ARRY) Appoints Victor Sa... [Published FierceBiotech - Sep 19 2014]
Array appoints Victor Sandor chief medical officer [Published PMLive - Sep 16 2014]
Allergic Rhinitis Treatment Market Global Techn... [Published MyNewsDesk - Sep 15 2014]
Array BioPharma hires Dr Victor Sandor as CMO f... [Published Individual.com - Sep 12 2014]
New medical chief at Array Bio [Published Seeking Alpha - Sep 12 2014]
Loxo Oncology Announces Second Quarter 2014 Fin... [Published Virtual Strategy Magazine - Sep 12 2014]
Loxo Oncology Announces Second Quarter 2014 Fin... [Published Pettinga Financial Advisors - Sep 12 2014]
Array BioPharma Appoints Victor Sandor, M.D., A... [Published Bio-Medicine - Sep 12 2014]
Array BioPharma : Appoints Victor Sandor, M.D.,... [Published 4 Traders - Sep 11 2014]
Array BioPharma Appoints Victor Sandor, M.D., A... [Published PR Newswire: General Business - Sep 11 2014]
Inflammatory Pain Therapeutics Pipeline Review ... [Published Individual.com - Sep 11 2014]
Array BioPharma's (ARRY) CEO Ron Squarer at Mor... [Published Seeking Alpha - Sep 10 2014]
June 2015 Options Now Available For Array BioPh... [Published Crawford Financial Planning - Sep 10 2014]
ASLAN Pharmaceuticals Pte Ltd Doses First Patie... [Published BioSpace - Sep 09 2014]
Stem Cell Transplant With Melphalan Preferred i... [Published American Journal of Public Health - Sep 04 2014]
Array BioPharma To Present At The Morgan Stanle... [Published ADVFN UK - Sep 03 2014]
Array BioPharma To Present At The Morgan Stanle... [Published Michigan Live - Sep 03 2014]
Array BioPharma To Present At The Morgan Stanle... [Published PR Newswire: Health - Sep 03 2014]
Array BioPharma Q4 net loss up [Published Individual.com - Sep 01 2014]
Array Biopharma Inc. Files SEC Form POSASR, Pos... [Published Crawford Financial Planning - Aug 28 2014]
Array Biopharma Inc. Files SEC Form POSASR, Pos... [Published HispanicBusiness.com - Aug 28 2014]
Patent Issued for Arylamino N-Heteraryl Compoun... [Published Pharmacy Choice - Aug 27 2014]
Five Billionaire-Owned Biotech Stocks You Could... [Published TheStreet.com - Aug 25 2014]
Five Billionaire-Owned Biotech Stocks You Could... [Published The Street Latest - Aug 25 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Phase 2 Trial Of Binimetinib In NRAS Melanoma S... [Published PR Newswire: Health - Sep 29 2014]
BOULDER, Colo., Sept. 29, 2014 /PRNewswire/ -- Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented today at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain.  ...
Array BioPharma Appoints Victor Sandor, M.D., A... [Published PR Newswire: General Business - Sep 11 2014]
BOULDER, Colo., Sept. 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced ...
Array BioPharma To Present At The Morgan Stanle... [Published PR Newswire: Health - Sep 03 2014]
BOULDER, Colo., Sept.  3, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Morgan Stanley 2014 Global Healthcare Conference in New York City.  The public is ...
Array BioPharma To Report Financial Results For... [Published PR Newswire: Health - Jul 28 2014]
BOULDER, Colo., July 28, 2014  Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the fourth quarter and full year of fiscal 2014 and hold a conference call to discuss those results on Tuesday, August 12, 2014.  Ron Squarer, Chief ...
Array BioPharma To Present At The Wells Fargo S... [Published PR Newswire: General Business - Jun 11 2014]
BOULDER, Colo., June 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Wells Fargo Securities 2014 Healthcare Conference in Boston.  The public is welcome ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Stock Updates on Biotech Industry - Array BioPh... [Published Financial Services - Sep 22 2014]
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
Array BioPharma Reports Financial Results For T... [Published Financial Services - Aug 12 2014]
Biotech Stocks Highlight -- Research on Celgene... [Published Financial Services - Jul 09 2014]
Study Updates, Market Activity, Preclinical Dat... [Published Financial Services - Jul 03 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.